Hail First Pharma Hires Investor Relations Firm DGR Advisors LLC
March 16 2011 - 1:14PM
Marketwired
Hail First Pharma Inc. announced today the hiring of Long Island
based DGR Advisors LLC as its investor relations firm.
DGR Advisors LLC will immediately take on the responsibility of
all incoming calls from investors inquiring on the Spencer
Pharmaceutical (PINKSHEETS: SPPH) buy-out transaction as well as
its initial public offering. DGR Advisors LLC has been retained for
a 12 month period and will be remunerated in cash, stock and
options of Hail First Pharma Inc. for a total compensation of
$120,000 and whereby the agreement may be renewed for an additional
12 months.
"DGR Advisors LLC is run by Robert Albi a seasoned Wall Street
professional, which comes highly recommended," said Hussain
Al-Awaid, Chairman of Hail First Pharma Inc. "We opted for Mr.
Albi, because our immediate need is for incoming inquiries and he
has extended experience in dealing with public transactions such as
the current buy-out transaction and our IPO," further added Mr.
Al-Awaid.
About Hail First Pharma
Hail First Pharma is a pharmaceutical company specializing in
acquiring, licensing and distributing of diabetic drugs, drug
delivery technology, nutritional products and medical
equipment.
Important Information About
Forward-Looking Statements in this press release may be
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as
"anticipate," "believe," "estimate," "expect," "intend" and similar
expressions, as they relate to the company or its management,
identify forward-looking statements. These statements are based on
current expectations, estimates and projections about the company's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and probably will,
differ materially from what is expressed or forecasted in such
forward-looking statements due to numerous factors, including those
described above. In addition, such statements could be affected by
risks and uncertainties related to the exploration for and
development of mineralized material, product demand, market and
customer acceptance, competition, pricing and development
difficulties, as well as general industry and market conditions and
growth rates and general economic conditions. Any forward-looking
statements speak only as of the date on which they are made, and
the company does not undertake any obligation to update any
forward-looking statement to reflect events or circumstances after
the date of this release. Information on the Company's website does
not constitute a part of this release.
Contact: Hail First Pharma Inc. Hussain Al-Awaid Chairman
hailfirstpharma@gmail.com DRG Advisors LLC Robert Albi
President Tel. 516-351-8562
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Nov 2023 to Nov 2024
